Hydrophilic polymer solubilization on norfloxacin solubility in preparation of solid dispersion

Powder Technology

Volumn 256, Issue , 2014, Pages 462-469

  Loh, Gabriel Onn Kit ^a   Tan, Yvonne Tze Fung ^a   Peh, Kok Khiang ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Hydrophilic polymers; Norfloxacin; Polymer complexation; Solid dispersions

Indexed keywords

ACETONE; CRYSTALLINITY; DISPERSIONS; DISSOLUTION; EVAPORATION; HYDROPHILICITY; POLYMERS; SOLUBILITY; SOLVENTS; WETTING;

HYDROPHILIC POLYMERS; HYDROXYPROPYL CELLULOSE; NORFLOXACIN; POLYMER COMPLEXATION; POORLY WATER-SOLUBLE DRUGS; SOLID DISPERSION; SOLID-STATE PROPERTIES; SOLVENT EVAPORATION METHOD;

DRUG DELIVERY;

ACETONE; HYDROXYPROPYLCELLULOSE; NORFLOXACIN; POLYACRYLIC ACID; POLYMER; POVIDONE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ADSORPTION; DRUG SOLUBILITY; ENTHALPY; EVAPORATION; INFRARED SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SOLID DISPERSION; SOLVENT EVAPORATION; X RAY DIFFRACTION;

EID: 84896399381     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2014.01.089     Document Type: Article

References (24)

1. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971, 60:1281-1302.
2. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
3. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve bioavailability of poorly water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
4. Lipinski C.A. Avoiding investment in doomed drugs, is poor solubility an industry wide problem?. Curr. Drug Discov. 2001, 4:17-19.
5. Guyot M., Fawaz F., Bildet J., Bonini F., Lagueny A.M. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. Int. J. Pharm. 1995, 123:53-63.
6. Kalaiselvan R., Mohanta G.P., Manna P.K., Manavalan R. Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline carriers. Indian J. Pharm. Sci. 2006, 68:599-607.
7. Josimar O.E., Juliana M.M. Solid dispersions containing ursolic acid in Poloxamer 407 and PEG 6000: a comparative study of fusion and solvent methods. Powder Technol. 2014, 253:98-106.
8. Sethia S., Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 2004, 272:1-10.
9. Yu M., Sun L., Li W., Lan Z., Li B., Tan L., Li M., Yang X. Investigation of structure and dissolution properties of a solid dispersion of lansoprazole in polyvinylpyrrolidone. J. Mol. Struct. 2011, 1005:70-77.
10. Rehab N.S., Mona B. Soluplus®: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation 2013, 237:406-414.
11. Fernando F., Josimar O.E., Carmen M.D., Marcia L.M., Juliana M.M. Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods. Powder Technol. 2013, 235:532-539.
12. Kim E.J., Chun M.K., Jang J.S., Lee I.H., Lee K.R., Choi H.K. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm. 2006, 64:200-205.
13. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267:79-91.
14. Moneghini M., Carcano A., Zingone G., Perissutti B. Studies in dissolution enhancement of atenolol. Part I. Int. J. Pharm. 1998, 175:177-183.
15. Waghmare A., Pore Y., Kuchekar B. Development and characterization of Zaleplon solid dispersion systems: a technical note. AAPS PharmSciTech 2008, 9:536-543.
16. Lee S., Nam K., Kim M.S., Jun S.W., Park J.S., Woo J.S., Hwang S.J. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch. Pharm. Res. 2005, 28:866-874.
17. Won D.H., Kim M.S., Lee S., Park J.S., Hwang S.J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int. J. Pharm. 2005, 301:199-208.
18. Khan K.A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 1975, 27:48-49.
19. Fawaza F., Bonini F., Guyot M., Bildet J., Maury M., Lagueny A.M. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion dispersions in rabbits. Int. J. Pharm. 1996, 132:271-275.
20. Vineet K.R., Harinath D., Narayan P.Y., Chandan S.C., Shubhini A.S. Solubility enhancement of miconazole nitrate: binary and ternary mixture approach. Drug Dev. Ind. Pharm. 2013, 1-9.
21. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
22. Ruan L.P., Yu B.Y., Fu G.M., Zhu D.N. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J. Pharm. Biomed. Anal. 2005, 38:457-464.
23. Yvonne T.F.T., Peh K.K., Othman A.H. Investigation of interpolymer dispersionation between carbopol and various grades of polyvinylpyrrolidone and effects on adhesion strength and swelling properties. J. Pharm. Pharm. Sci. 2001, 4:7-14.
24. Sahoo S., Chakraborti C.K., Behera P.K., Mishra S.C. FTIR and Raman spectroscopic investigations of a norfloxacin/carbopol934 polymeric suspension. J. Young Pharm. 2012, 4:138-145.